VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ASMB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ASMBAssembly Biosciences, Inc.
$22.50$444M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ASMB logo

Assembly Biosciences, Inc.

ASMB
NASDAQ · Vaccines & Infectious Disease
$22.50
At close - Nov 17, 4:00 PM EST - USD
Market Cap$446M
P/E-44.1x
52W High$39.71
Volume326.39K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Milestone Revenue Masks Persistent Operational Cash Burn

Assembly Biosciences' investment thesis is a high-risk, binary bet on clinical pipeline execution, with its financials dominated by lumpy collaboration revenue rather than sustainable commercial traction.

GrowthMixed
ProfitabilityStrained
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

ASMB price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

-226% Peers

P/E is 226% below peer median

03

Market leadership

RS 29 · Lag

Laggard (Underperforming 71% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 12

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ASMB-33.31%
S&P 500 (^GSPC)+7.21%
1-Year Return
ASMB-38.07%
S&P 500 (^GSPC)+10.03%
3-Year Return
ASMB+160.42%
S&P 500 (^GSPC)+67.66%
5-Year Return
ASMB-24.70%
S&P 500 (^GSPC)+70.09%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$72M+153.5% YoY
Net income FY25
-$6M+84.8% YoY
Free cash flow FY25
-$41M+19.5% YoY
Operating margin FY25
-16.8%+142.5 pts YoY
ROIC (FY25)-12.2%
Avg ROIC 5Y-128.7%
ROE (TTM)-4.4%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate7/12 (70%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 12, 2026
-$0.93-42.0%
vs -$0.66
$3M-67.4%
vs $9M
Q3 2026
Aug 13, 2026
-$0.20+72.4%
vs -$0.72
$13M+55.5%
vs $9M
Q2 2026
May 7, 2026
-$0.54+26.0%
vs -$0.73
$8M-11.4%
vs $9M
Q2 2026
Mar 19, 2026
$2.48+586.3%
vs -$0.51
$42M+472.2%
vs $7M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·6d ago
Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to a loss of $0.72 per share a year ago.

GlobeNewsWire·6d ago
Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates

– Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection –

GlobeNewsWire·Nov 2, 2026
Assembly Biosciences to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present and participate in one-on-one meetings at the following upcoming investor conferences in November:

GlobeNewsWire·Oct 29, 2026
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus

– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the fourth quarter of 2027 –

Filtered for Assembly Biosciences, Inc.More Headlines
04

Compare before deciding

Benchmark ASMB against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Assembly Biosciences, Inc. (ASMB)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ASMB logoASMBAssembly Biosciences, Inc.Current
$22.50$445.89M-44.14153.52%-16.57%-4.4%—
ARWR logoARWRArrowhead Pharmaceuticals, Inc.
$42.99$6.06B-8.41-45.65%-160.64%-172.62%—
RCKT logoRCKTRocket Pharmaceuticals, Inc.
$2.11$230.4M-14.85——-5.34%—
REPL logoREPLReplimune Group, Inc.
$19.69$1.65B-7.64——-157.78%—
GILD logoGILDGilead Sciences, Inc.
$170.26$211.39B-55.142.39%-12.47%-21.84%1.87%
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$957.76$98.67B20.990.99%28.51%15.07%0.36%

Compare ASMB vs Peers

Assembly Biosciences, Inc. (ASMB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ARWR

Most directly comparable listed peer for ASMB.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare ASMB against a more recognizable public peer.

Peer Set

Compare Top 5

vs ARWR, RCKT, REPL, GILD

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ASMB SEC Filings & Documents

Assembly Biosciences, Inc. (ASMB) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 13, 2026·SEC

Material company update

Jun 5, 2026·SEC

Material company update

May 26, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 19, 2026·SEC

FY 2025

Mar 20, 2025·SEC

FY 2024

Mar 28, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 13, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 10, 2025·SEC

Get notified when ASMB posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ASMB Frequently Asked Questions

Assembly Biosciences, Inc. (ASMB) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Assembly Biosciences, Inc.'s revenue?

Assembly Biosciences, Inc. (ASMB) reported $67.0M in revenue over the trailing twelve months. Revenue was $72.3M in fiscal year 2025.

How fast is Assembly Biosciences, Inc. growing?

Assembly Biosciences, Inc. (ASMB) grew revenue by 80.2% over the trailing twelve months, compared with the twelve months before.

Is ASMB profitable?

No. Assembly Biosciences, Inc. (ASMB) reported a net loss of $11.1M over the trailing twelve months.

Dividend & Returns
What is ASMB's return on equity?

Assembly Biosciences, Inc. (ASMB) had a return on equity (ROE) of -4.4% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Assembly Biosciences, Inc.'s free cash flow?

Assembly Biosciences, Inc. (ASMB) had negative free cash flow of $40.7M over the trailing twelve months.

What if you invested $1,000 in ASMB back in 2008?

Total return calculator · dividends reinvested · 18+ years of data

See returns →